← Eichor
Condition: Brca2 Gene Mutation Synced from ClinicalTrials.gov · July 28, 2026

Recruiting studies: Brca2 Gene Mutation

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Analysing Outcomes After Prostate Cancer Diagnosis and Treatment in Carriers of Rare Germline Mutations
Phase N/A · 1 location(s) · Institute of Cancer Research, United Kingdom · NCT02705846Novel Neoadjuvant and Adjuvant Strategy for Germline BRCA 1/2 Mutated Triple Negative Breast Cancer
Phase 2 · 3 location(s) · Okayama University · NCT05485766BRCA Mutation Carriers' Platform a Multicenter Study
Phase N/A · 40 location(s) · Fondazione Policlinico Universitario Agostino Gemelli IRCCS · NCT07253051Cognitive Behavioral Therapy for Fear of Cancer Recurrence in Women With BRCA1/2 Gene
NA · 1 location(s) · CHU de Quebec-Universite Laval · NCT06817694Liquid Biopsy Evaluation and Repository Development at Princess Margaret
Phase N/A · 1 location(s) · University Health Network, Toronto · NCT03702309An Intervention to Increase Genetic Testing in Families Who May Share a Gene Mutation Related to Cancer Risk and An Inte
NA · 8 location(s) · Memorial Sloan Kettering Cancer Center · NCT05420064Olaparib and ASTX727 in BRCA1/2- and Homologous Recombination Deficient (HRD)-Mutated Tumors
Phase 1 · 1 location(s) · Varun Monga, MBBS · NCT06177171TUBectomy With Delayed Oophorectomy in High Risk Women to Assess the Safety of Prevention
NA · 66 location(s) · University Medical Center Nijmegen · NCT04294927MEASUREMENT OF CIRCULATING MUTATION BURDEN
Phase N/A · 1 location(s) · Centre Francois Baclesse · NCT06792721SHARON: A Clinical Trial for Metastatic Cancer Using Chemotherapy and Patients' Own Stem Cells
Phase 1 · 2 location(s) · General Oncology, Inc. · NCT04150042Pancreas Registry and High Risk Registry
Phase N/A · 2 location(s) · Icahn School of Medicine at Mount Sinai · NCT02775461Contribution of Oncogenetics in Breast Cancer in Reunion Epidemiology of Breast Cancer in Reunion: Study of the Reunion
NA · 1 location(s) · Centre Hospitalier Universitaire de la Réunion · NCT05898009Combination Therapy in Cancers With Mutations in DNA Repair Genes
Phase 1 · 1 location(s) · University of California, San Francisco · NCT05694715A Study of PARG Inhibitor ETX-19477 in Patients With Advanced Solid Malignancies
Phase 1/Phase 2 · 14 location(s) · 858 Therapeutics, Inc. · NCT06395519Study of CX-5461 in Patients With Solid Tumours and BRCA1/2, PALB2 or Homologous Recombination Deficiency (HRD) Mutation
Phase 1 · 8 location(s) · Senhwa Biosciences, Inc. · NCT04890613Olaparib With Cediranib or AZD6738 for the Treatment of Advanced or Metastatic Germline BRCA Mutated Breast Cancer
Phase 2 · 1 location(s) · M.D. Anderson Cancer Center · NCT04090567A Study of Changes in Ki67 Expression in People With Breast Cancer Receiving Endocrine Therapy Before Surgery
NA · 1 location(s) · Memorial Sloan Kettering Cancer Center · NCT06127979A Prospective CohorT Study of HandX - Assisted ENdoscopic MAstectomy: Feasibility and Safety (ATHENA I Study)
NA · 1 location(s) · Vasileios Kalles · NCT07292246Registry of Subjects at Risk of Pancreatic Cancer
Phase N/A · 4 location(s) · Associazione Italiana per lo Studio del Pancreas · NCT04095195Study of ACE-86225106 to Treat Patients With Advanced Solid Tumors
Phase 1/Phase 2 · 14 location(s) · Acerand Therapeutics (Shanghai) Limited · NCT06380660Evaluating the Addition of Elacestrant (Oral SERD) to Olaparib (PARP-inhibitor) in Patients With Advanced/Metastatic HR+
Phase 2 · 36 location(s) · GBG Forschungs GmbH · NCT06201234Prophylactic Irradiation to the Contralateral Breast for BCAs Patients
NA · 8 location(s) · Second Affiliated Hospital, School of Medicine, Zhejiang Uni · NCT04960839The Cancer of the Pancreas Screening-5 CAPS5)Study
Phase 3 · 9 location(s) · Johns Hopkins University · NCT02000089COsegregation of VARiants in Panel of Genes
NA · 62 location(s) · Institut Curie · NCT01689584Prostate Cancer Genetic Risk Evaluation and Screening Study
Phase N/A · 1 location(s) · Massachusetts General Hospital · NCT05129605Phase Ib Study of Axatilimab in Combination With Olaparib in BRCA1/2 and PALB2- Associated Metastatic HER2-negative Brea
Phase 1 · 3 location(s) · Dana-Farber Cancer Institute · NCT06488378Hormone Replacement Therapy After Risk Reducing Salpingo-oophorectomy
NA · 2 location(s) · Duke University · NCT06972719Impact of Consumption of Ultra-processed Foods in Individuals at High Risk of Cancer
NA · 3 location(s) · Gustave Roussy, Cancer Campus, Grand Paris · NCT07436312Carboplatin Chemotherapy Before Surgery for People With High-Risk Prostate Cancer and an Inherited BRCA1 or BRCA2 Gene M
Phase 2 · 133 location(s) · SWOG Cancer Research Network · NCT05806515APOLLO: A Randomized Phase II Double-Blind Study of Olaparib Versus Placebo Following Curative Intent Therapy in Patient
Phase 2 · 454 location(s) · National Cancer Institute (NCI) · NCT04858334
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.